For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.
Adverse Events Module path is as follows:
Study -> Results Section -> Adverse Events Module -> Event Groups
Study -> Results Section -> Adverse Events Module -> Serious Events
Study -> Results Section -> Adverse Events Module -> Other Events
| Title | Description | Deaths # Affected | Deaths # At Risk | Serious # Affected | Serious # At Risk | Other # Affected | Other # At Risk | View |
|---|---|---|---|---|---|---|---|---|
| Fluoxetine | Dosing will be * Week 1-4: 20 mg daily * Week 5-8: 40 mg daily * Week 9-12: 60 mg daily * Week 13-24: 80 mg daily Fluoxetine | 0 | None | 0 | 8 | 8 | 8 | View |
| Term | Type | Organ System | Vocab | View |
|---|---|---|---|---|
| headaches | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| excessive yawning | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| anxiety | NON_SYSTEMATIC_ASSESSMENT | Psychiatric disorders | None | View |
| diarrhea | NON_SYSTEMATIC_ASSESSMENT | Gastrointestinal disorders | None | View |
| acute bronchitis | NON_SYSTEMATIC_ASSESSMENT | Respiratory, thoracic and mediastinal disorders | None | View |
| fatigue | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |
| increased palpitations | NON_SYSTEMATIC_ASSESSMENT | Cardiac disorders | None | View |
| dizziness | NON_SYSTEMATIC_ASSESSMENT | General disorders | None | View |